Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson’s Disease

Existing therapies for Parkinson’s disease (PD) are only symptomatic. As erythropoietin (EPO) is emerging for its benefits in neurodegenerative diseases, here, we test the protective effect driven by EPO in in vitro (SH-SY5Y cells challenged by MPP⁺) and in vivo (C57BL/6J mice administere...

Descripción completa

Detalles Bibliográficos

Autores principales:	Federica Rey, Sara Ottolenghi, Toniella Giallongo, Alice Balsari, Carla Martinelli, Robert Rey, Raffaele Allevi, Anna Maria Di Giulio, Gian Vincenzo Zuccotti, Serena Mazzucchelli, Roberta Foresti, Michele Samaja, Stephana Carelli
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2021-01-01
Colección:	Antioxidants
Materias:	erythropoietin (EPO) redox imbalance Parkinson’s disease mitochondrial metabolism neuroprotection tyrosine hydroxylase (TH)
Acceso en línea:	https://www.mdpi.com/2076-3921/10/1/121
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!